annual CFF:
-$1.49B-$932.70M(-165.90%)Summary
- As of today (May 21, 2025), VRTX annual cash flow from financing activities is -$1.49 billion, with the most recent change of -$932.70 million (-165.90%) on December 31, 2024.
- During the last 3 years, VRTX annual CFF has fallen by -$16.90 million (-1.14%).
- VRTX annual CFF is now -249.64% below its all-time high of $999.01 million, reached on December 31, 2009.
Performance
VRTX Cash from financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFF:
-$680.40M-$289.10M(-73.88%)Summary
- As of today (May 21, 2025), VRTX quarterly cash flow from financing activities is -$680.40 million, with the most recent change of -$289.10 million (-73.88%) on March 31, 2025.
- Over the past year, VRTX quarterly CFF has dropped by -$322.90 million (-90.32%).
- VRTX quarterly CFF is now -226.31% below its all-time high of $538.66 million, reached on December 31, 2009.
Performance
VRTX quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
-$1.82B-$322.90M(-21.60%)Summary
- As of today (May 21, 2025), VRTX TTM cash flow from financing activities is -$1.82 billion, with the most recent change of -$322.90 million (-21.60%) on March 31, 2025.
- Over the past year, VRTX TTM CFF has dropped by -$1.19 billion (-190.85%).
- VRTX TTM CFF is now -281.96% below its all-time high of $999.01 million, reached on December 31, 2009.
Performance
VRTX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
VRTX Cash from financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -165.9% | -90.3% | -190.8% |
| 3 y3 years | -1.1% | -613.2% | -72.3% |
| 5 y5 years | -1278.9% | -89.3% | -853.5% |
VRTX Cash from financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -2108.1% | at low | -1526.4% | at low | -2585.1% | at low |
| 5 y | 5-year | -1278.9% | at low | -666.9% | at low | -3055.8% | at low |
| alltime | all time | -249.6% | at low | -226.3% | at low | -282.0% | at low |
VRTX Cash from financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$680.40M(+73.9%) | -$1.82B(+21.6%) |
| Dec 2024 | -$1.49B(+165.9%) | -$391.30M(+1.0%) | -$1.49B(+22.2%) |
| Sep 2024 | - | -$387.50M(+8.1%) | -$1.22B(+22.2%) |
| Jun 2024 | - | -$358.60M(+0.3%) | -$1.00B(+60.1%) |
| Mar 2024 | - | -$357.50M(+198.4%) | -$625.00M(+11.2%) |
| Dec 2023 | -$562.20M(+730.4%) | -$119.80M(-27.4%) | -$562.20M(+39.8%) |
| Sep 2023 | - | -$165.00M(-1053.8%) | -$402.20M(+35.2%) |
| Jun 2023 | - | $17.30M(-105.9%) | -$297.40M(+11.4%) |
| Mar 2023 | - | -$294.70M(-833.1%) | -$267.00M(+294.4%) |
| Dec 2022 | -$67.70M(-95.4%) | $40.20M(-166.8%) | -$67.70M(-84.8%) |
| Sep 2022 | - | -$60.20M(-226.2%) | -$444.10M(-57.3%) |
| Jun 2022 | - | $47.70M(-150.0%) | -$1.04B(-1.3%) |
| Mar 2022 | - | -$95.40M(-71.6%) | -$1.05B(-28.6%) |
| Dec 2021 | -$1.48B(+192.5%) | -$336.20M(-48.8%) | -$1.48B(+16.7%) |
| Sep 2021 | - | -$656.70M(-2054.5%) | -$1.27B(+68.7%) |
| Jun 2021 | - | $33.60M(-106.5%) | -$751.00M(+13.0%) |
| Mar 2021 | - | -$518.70M(+314.3%) | -$664.57M(+31.5%) |
| Dec 2020 | -$505.30M(-498.5%) | -$125.21M(-11.0%) | -$505.30M(+131.1%) |
| Sep 2020 | - | -$140.68M(-217.2%) | -$218.64M(+279.6%) |
| Jun 2020 | - | $120.03M(-133.4%) | -$57.60M(-69.8%) |
| Mar 2020 | - | -$359.43M(-322.6%) | -$190.64M(-250.3%) |
| Dec 2019 | $126.80M(-278.0%) | $161.45M(+693.1%) | $126.80M(-193.4%) |
| Sep 2019 | - | $20.36M(-256.4%) | -$135.69M(-11.9%) |
| Jun 2019 | - | -$13.02M(-69.0%) | -$153.97M(-19.9%) |
| Mar 2019 | - | -$41.99M(-58.4%) | -$192.16M(+169.8%) |
| Dec 2018 | -$71.22M(-204.1%) | -$101.05M(-4960.3%) | -$71.22M(-169.1%) |
| Sep 2018 | - | $2.08M(-104.1%) | $103.06M(-59.4%) |
| Jun 2018 | - | -$51.21M(-164.9%) | $253.68M(-41.9%) |
| Mar 2018 | - | $78.96M(+7.8%) | $436.93M(+538.7%) |
| Dec 2017 | $68.40M(-48.7%) | $73.23M(-52.0%) | $68.40M(-23.1%) |
| Sep 2017 | - | $152.71M(+15.7%) | $88.94M(-277.1%) |
| Jun 2017 | - | $132.03M(-145.6%) | -$50.22M(-68.8%) |
| Mar 2017 | - | -$289.56M(-408.8%) | -$161.00M(-220.8%) |
| Dec 2016 | $133.27M(-29.5%) | $93.76M(+591.8%) | $133.27M(+44.6%) |
| Sep 2016 | - | $13.55M(-36.2%) | $92.15M(-28.2%) |
| Jun 2016 | - | $21.25M(+352.0%) | $128.26M(-10.4%) |
| Mar 2016 | - | $4.70M(-91.1%) | $143.21M(-24.2%) |
| Dec 2015 | $188.92M(-65.6%) | $52.64M(+6.0%) | $188.92M(-22.7%) |
| Sep 2015 | - | $49.67M(+37.2%) | $244.46M(-55.7%) |
| Jun 2015 | - | $36.20M(-28.2%) | $552.03M(+0.5%) |
| Mar 2015 | - | $50.41M(-53.4%) | $549.24M(-0.0%) |
| Dec 2014 | $549.24M(+121.1%) | $108.19M(-69.7%) | $549.24M(+4.6%) |
| Sep 2014 | - | $357.23M(+969.4%) | $525.11M(+190.3%) |
| Jun 2014 | - | $33.41M(-33.7%) | $180.88M(-40.7%) |
| Mar 2014 | - | $50.42M(-40.0%) | $304.96M(+22.8%) |
| Dec 2013 | $248.41M(+44.3%) | $84.05M(+546.3%) | $248.41M(+46.8%) |
| Sep 2013 | - | $13.01M(-91.7%) | $169.20M(+3.0%) |
| Jun 2013 | - | $157.49M(-2667.0%) | $164.34M(+13.7%) |
| Mar 2013 | - | -$6.13M(-226.8%) | $144.54M(-16.1%) |
| Dec 2012 | $172.20M(-238.6%) | $4.84M(-40.7%) | $172.20M(-1203.0%) |
| Sep 2012 | - | $8.15M(-94.1%) | -$15.61M(+322.7%) |
| Jun 2012 | - | $137.69M(+539.7%) | -$3.69M(-95.7%) |
| Mar 2012 | - | $21.52M(-111.8%) | -$86.36M(-30.5%) |
| Dec 2011 | -$124.24M(-129.2%) | -$182.98M(-1011.8%) | -$124.24M(-282.2%) |
| Sep 2011 | - | $20.07M(-63.5%) | $68.19M(-84.7%) |
| Jun 2011 | - | $55.03M(-436.4%) | $446.62M(+11.4%) |
| Mar 2011 | - | -$16.36M(-273.1%) | $401.06M(-5.6%) |
| Dec 2010 | $425.06M(-57.5%) | $9.45M(-97.6%) | $425.06M(-55.5%) |
| Sep 2010 | - | $398.50M(+4106.6%) | $954.27M(+39.0%) |
| Jun 2010 | - | $9.47M(+24.0%) | $686.37M(-0.2%) |
| Mar 2010 | - | $7.64M(-98.6%) | $687.98M(-31.1%) |
| Dec 2009 | $999.01M(+60.9%) | $538.66M(+312.5%) | $999.01M(+110.7%) |
| Sep 2009 | - | $130.59M(+1078.5%) | $474.06M(-16.6%) |
| Jun 2009 | - | $11.08M(-96.5%) | $568.43M(+3.8%) |
| Mar 2009 | - | $318.67M(+2223.5%) | $547.43M(-11.8%) |
| Dec 2008 | $620.74M | $13.71M(-93.9%) | $620.74M(+0.5%) |
| Sep 2008 | - | $224.96M(-2368.2%) | $617.75M(+71.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2008 | - | -$9.92M(-102.5%) | $360.39M(-4.8%) |
| Mar 2008 | - | $391.98M(+3554.1%) | $378.44M(-3813.9%) |
| Dec 2007 | -$10.19M(-102.8%) | $10.73M(-133.1%) | -$10.19M(+54.0%) |
| Sep 2007 | - | -$32.40M(-498.2%) | -$6.62M(-101.9%) |
| Jun 2007 | - | $8.14M(+143.3%) | $345.64M(-0.4%) |
| Mar 2007 | - | $3.34M(-76.6%) | $347.05M(-5.1%) |
| Dec 2006 | $365.87M(+85.3%) | $14.30M(-95.5%) | $365.87M(-0.4%) |
| Sep 2006 | - | $319.85M(+3249.6%) | $367.20M(+521.1%) |
| Jun 2006 | - | $9.55M(-56.9%) | $59.12M(-73.0%) |
| Mar 2006 | - | $22.16M(+41.7%) | $219.04M(+10.9%) |
| Dec 2005 | $197.46M(-2389.1%) | $15.64M(+32.9%) | $197.46M(+6.6%) |
| Sep 2005 | - | $11.77M(-93.1%) | $185.29M(+7.5%) |
| Jun 2005 | - | $169.47M(>+9900.0%) | $172.43M(-2257.3%) |
| Mar 2005 | - | $572.00K(-83.6%) | -$7.99M(-7.3%) |
| Dec 2004 | -$8.63M(-123.0%) | $3.48M(-417.9%) | -$8.63M(-288.5%) |
| Sep 2004 | - | -$1.09M(-90.0%) | $4.58M(-68.8%) |
| Jun 2004 | - | -$10.95M(>+9900.0%) | $14.64M(-44.5%) |
| Mar 2004 | - | -$61.00K(-100.4%) | $26.40M(-29.5%) |
| Dec 2003 | $37.47M(+170.7%) | $16.68M(+85.9%) | $37.47M(+36.6%) |
| Sep 2003 | - | $8.97M(+1016.2%) | $27.44M(+42.2%) |
| Jun 2003 | - | $804.00K(-92.7%) | $19.30M(-17.1%) |
| Mar 2003 | - | $11.01M(+65.6%) | $23.27M(+68.1%) |
| Dec 2002 | $13.84M(-376.3%) | $6.65M(+698.1%) | $13.84M(-246.9%) |
| Sep 2002 | - | $833.00K(-82.6%) | -$9.42M(+5.7%) |
| Jun 2002 | - | $4.78M(+201.8%) | -$8.92M(-19.0%) |
| Mar 2002 | - | $1.58M(-109.5%) | -$11.02M(+119.9%) |
| Dec 2001 | -$5.01M(-100.8%) | -$16.62M(-1342.0%) | -$5.01M(-105.1%) |
| Sep 2001 | - | $1.34M(-50.1%) | $97.50M(-77.9%) |
| Jun 2001 | - | $2.68M(-64.7%) | $441.65M(-1.6%) |
| Mar 2001 | - | $7.59M(-91.2%) | $448.86M(-27.5%) |
| Dec 2000 | $619.33M(>+9900.0%) | $85.89M(-75.1%) | $619.33M(+15.9%) |
| Sep 2000 | - | $345.49M(+3395.4%) | $534.33M(+181.5%) |
| Jun 2000 | - | $9.88M(-94.4%) | $189.84M(+5.3%) |
| Mar 2000 | - | $178.06M(>+9900.0%) | $180.26M(+6337.8%) |
| Dec 1999 | $2.80M(-33.3%) | $900.00K(-9.7%) | $2.80M(+40.0%) |
| Sep 1999 | - | $997.00K(+229.0%) | $2.00M(-20.1%) |
| Jun 1999 | - | $303.00K(-49.5%) | $2.50M(-28.5%) |
| Mar 1999 | - | $600.00K(+500.0%) | $3.50M(-16.7%) |
| Dec 1998 | $4.20M(-97.5%) | $100.00K(-93.3%) | $4.20M(-26.3%) |
| Sep 1998 | - | $1.50M(+15.4%) | $5.70M(+7.5%) |
| Jun 1998 | - | $1.30M(0.0%) | $5.30M(-66.9%) |
| Mar 1998 | - | $1.30M(-18.8%) | $16.00M(-90.3%) |
| Dec 1997 | $164.80M(+89.2%) | $1.60M(+45.5%) | $164.80M(-0.6%) |
| Sep 1997 | - | $1.10M(-90.8%) | $165.80M(-31.7%) |
| Jun 1997 | - | $12.00M(-92.0%) | $242.80M(+2.5%) |
| Mar 1997 | - | $150.10M(+5673.1%) | $236.80M(+171.9%) |
| Dec 1996 | $87.10M(+5023.5%) | $2.60M(-96.7%) | $87.10M(+2.2%) |
| Sep 1996 | - | $78.10M(+1201.7%) | $85.20M(+1100.0%) |
| Jun 1996 | - | $6.00M(+1400.0%) | $7.10M(+317.6%) |
| Mar 1996 | - | $400.00K(-42.9%) | $1.70M(0.0%) |
| Dec 1995 | $1.70M(-97.6%) | $700.00K(>+9900.0%) | $1.70M(-89.3%) |
| Sep 1995 | - | $0.00(-100.0%) | $15.90M(+1.9%) |
| Jun 1995 | - | $600.00K(+50.0%) | $15.60M(+5.4%) |
| Mar 1995 | - | $400.00K(-97.3%) | $14.80M(-79.4%) |
| Dec 1994 | $71.90M(+4393.8%) | $14.90M(-5066.7%) | $71.90M(+27.0%) |
| Sep 1994 | - | -$300.00K(+50.0%) | $56.60M(+0.4%) |
| Jun 1994 | - | -$200.00K(-100.3%) | $56.40M(-5.2%) |
| Mar 1994 | - | $57.50M(<-9900.0%) | $59.50M(+3618.8%) |
| Dec 1993 | $1.60M(-233.3%) | -$400.00K(-20.0%) | $1.60M(-5.9%) |
| Sep 1993 | - | -$500.00K(-117.2%) | $1.70M(-10.5%) |
| Jun 1993 | - | $2.90M(-825.0%) | $1.90M(-246.2%) |
| Mar 1993 | - | -$400.00K(+33.3%) | -$1.30M(+8.3%) |
| Dec 1992 | -$1.20M(-102.4%) | -$300.00K(0.0%) | -$1.20M(+33.3%) |
| Sep 1992 | - | -$300.00K(0.0%) | -$900.00K(+50.0%) |
| Jun 1992 | - | -$300.00K(0.0%) | -$600.00K(+100.0%) |
| Mar 1992 | - | -$300.00K | -$300.00K |
| Dec 1991 | $50.90M | - | - |
FAQ
- What is Vertex Pharmaceuticals Incorporated annual cash flow from financing activities?
- What is the all time high annual CFF for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated annual CFF year-on-year change?
- What is Vertex Pharmaceuticals Incorporated quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated quarterly CFF year-on-year change?
- What is Vertex Pharmaceuticals Incorporated TTM cash flow from financing activities?
- What is the all time high TTM CFF for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated TTM CFF year-on-year change?
What is Vertex Pharmaceuticals Incorporated annual cash flow from financing activities?
The current annual CFF of VRTX is -$1.49B
What is the all time high annual CFF for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high annual cash flow from financing activities is $999.01M
What is Vertex Pharmaceuticals Incorporated annual CFF year-on-year change?
Over the past year, VRTX annual cash flow from financing activities has changed by -$932.70M (-165.90%)
What is Vertex Pharmaceuticals Incorporated quarterly cash flow from financing activities?
The current quarterly CFF of VRTX is -$680.40M
What is the all time high quarterly CFF for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high quarterly cash flow from financing activities is $538.66M
What is Vertex Pharmaceuticals Incorporated quarterly CFF year-on-year change?
Over the past year, VRTX quarterly cash flow from financing activities has changed by -$322.90M (-90.32%)
What is Vertex Pharmaceuticals Incorporated TTM cash flow from financing activities?
The current TTM CFF of VRTX is -$1.82B
What is the all time high TTM CFF for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high TTM cash flow from financing activities is $999.01M
What is Vertex Pharmaceuticals Incorporated TTM CFF year-on-year change?
Over the past year, VRTX TTM cash flow from financing activities has changed by -$1.19B (-190.85%)